SENORES · NSE
Senores Pharmaceuticals Limited
₹1,402.6
+0.00% (₹0)
Prev. close
₹1,402.6
Volume
3,25,710
Delivery %
49.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, nutritional supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Swapnil Jatinbhai Shah
Headquarters
Ahmedabad
Employees
368
Website
senorespharma.comExchange
View on NSE ↗Key stats
Market cap
₹6,459.48 Cr
P/E ratio (TTM)
49.5
EPS (TTM)
₹28.33
Beta (1Y · daily vs NIFTY 50)
0.94
Shares float
2.13 Cr
EPS · quarter ended Jun 2026
₹6.60
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹35.33 Cr | ₹210.78 Cr | ₹398.25 Cr | ₹632.63 Cr | |
| EBITDA | ₹16.05 Cr | ₹43.46 Cr | ₹108.96 Cr | ₹215.38 Cr |
| ₹8.43 Cr | ₹31.45 Cr | ₹58.56 Cr | ₹115.38 Cr | |
| Diluted EPS | ₹1.83 | ₹6.83 | ₹16.12 | ₹26.39 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹131.05 Cr | ₹621.88 Cr | ₹1,226.86 Cr | ₹1,603.81 Cr | |
| ₹62.59 Cr | ₹257.64 Cr | ₹314.75 Cr | ₹342.01 Cr | |
| Stockholders' equity | ₹45.50 Cr | ₹204.27 Cr | ₹786.18 Cr | ₹933.60 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-1.08 Cr | ₹-25.70 Cr | ₹-45.92 Cr | ₹62.05 Cr | |
| Investing cash flow | ₹-48.29 Cr | ₹-54.23 Cr | ₹-429.48 Cr | ₹-120.56 Cr |
| ₹46.25 Cr | ₹86.98 Cr | ₹573.14 Cr | ₹-1.32 Cr | |
| Capital expenditure | ₹-47.28 Cr | ₹-51.83 Cr | ₹-157.52 Cr | ₹-264.73 Cr |
| End cash position | ₹10.00 L | ₹7.65 Cr | ₹105.39 Cr | ₹45.55 Cr |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|
| Promoter | 45.76% | 45.77% | 45.78% | 45.80% | 45.82% |
| Public | 54.24% | 54.23% | 54.22% | 54.20% | 54.18% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Senores Pharmaceuticals Limited | ₹6,517.50 Cr | ₹1,402.6 | 49.0 | 6.98 | 12.4% | 0.37 | +61.4% | +95.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
SENORES Share Price Rises 5.04% | Market Cap Rs 6,572 Cr
SENORES Pharmaceuticals' share price rose 5.04% to Rs 1,499, reaching a market capitalization of Rs 6,572 crore. This movement occurred without a specific company-related catalyst, placing it among the day's notable gainers in the Indian stock market. The stock's valuation profile is currently richer than the broader healthcare industry median.
Senores Pharma targets ₹3,000 crore revenue in 3-5 years, expands India and US capacity
Senores Pharmaceuticals aims for ₹2,500-3,000 crore revenue within 3-5 years, driven by expanding manufacturing capacity in India and the US. The company plans to add a fourth commercial line in the US and commercialize its Atlanta sterile injections facility within 12-18 months. Senores also reported a 30.6% rise in Q1FY27 revenue to ₹180.21 crore.